FDA announced that it issued a "safe to proceed" letter to Revolution Medicines, clearing the company to open an expanded access treatment protocol (EAP) for daraxonrasib, its investigational pancreatic cancer drug. Revolution Medicines identifies daraxonrasib, also known as RMC-6236, as a RAS(ON) multi-selective inhibitor currently in the Phase 3 RASolute 302 trial for previously treated metastatic pancreatic ductal adenocarcinoma.
Coverage of this announcement has focused on the clinical angle: patients, physicians, and access to an unapproved therapy. That's the visible layer. Underneath it sits a set of manufacturing and quality obligations that apply the moment a sponsor's expanded access population grows past a handful of individual patients. If you manage a quality system, run audits, or sit inside a manufacturing or supply chain function that supports investigational drug production, this announcement is a useful, current case study in what changes and what doesn't.
What FDA Actually Announced
Per FDA's press release, the agency issued Revolution Medicines a "safe to proceed" letter authorizing the company to initiate an expanded access treatment protocol for daraxonrasib. The key word is "permits." FDA is not approving the drug. It is not saying the drug works. It is confirming that a sponsor may distribute an investigational product outside the controlled trial generating the evidence for approval, under the framework in 21 CFR Part 312, Subpart I.
Those are two separate regulatory acts. An EAP authorization tells you FDA reviewed a distribution mechanism and didn't block it. It says nothing about the eventual marketing decision.
Expanded Access, in Plain Terms
Expanded access, sometimes called compassionate use, lets FDA authorize an investigational drug for use outside a clinical trial. Two conditions have to be true: the patient has a serious or immediately life-threatening disease with no comparable or satisfactory alternative therapy, and the potential benefit justifies the risk given how severe the disease is. The regulation splits into three pathways based on how many patients are covered.
| Pathway | Governing Regulation | Who It Covers | FDA Review Trigger |
|---|---|---|---|
| Individual patient, emergency | 21 CFR 312.310(d) | One patient, immediate life-threatening situation | FDA can authorize by phone before the written submission is filed |
| Individual patient, non-emergency | 21 CFR 312.310(a) | One patient | Sponsor or physician needs FDA authorization before starting treatment |
| Intermediate-size population | 21 CFR 312.315 | A defined group sharing one disease, too large for single-patient use | FDA authorization required before use begins |
| Widespread treatment use | 21 CFR 312.320 | Broad population, such as the daraxonrasib EAP | Effective 30 days after FDA receipt unless FDA places it on clinical hold |
Daraxonrasib's EAP falls into the last row. A treatment protocol under 312.320 requires the sponsor to show three things. The drug must already be under investigation in a controlled trial, or have completed its trials. The sponsor must be pursuing marketing approval with due diligence. And the disease must be serious or immediately life-threatening, with no comparable alternative. Pancreatic ductal adenocarcinoma fits that last condition about as clearly as any solid tumor does: prognosis is poor, and treatment options for patients who've already failed prior therapy are limited.
What "Safe to Proceed" Actually Means
A "safe to proceed" letter is not a new approval track. It communicates the outcome of the same 30-day review window that governs any submission under 21 CFR 312.40. A treatment protocol under 312.320 takes effect 30 days after FDA receives it unless the agency places it on clinical hold. FDA notifying Revolution Medicines that it may proceed is FDA confirming it reviewed the submission and chose not to exercise that hold authority. The letter is a transparency tool, not a separate legal gate.
If you're a sponsor watching this and wondering whether you need an explicit letter before your own EAP can move forward, you don't, as a matter of regulation. If FDA takes no action within 30 days, the protocol is in effect. FDA sends the letter for high-profile programs, or when there's public interest in visibility around access to an investigational therapy.
Why This Doesn't Pause the Quality System
An EAP authorization is a distribution decision, not a manufacturing exemption. Product supplied under a treatment protocol still has to come from a controlled, audited supply chain, and the quality obligations that apply to trial material largely follow the product into expanded access.
- CGMP still applies. Investigational drug substance and product used in a Phase 3 program, and in an EAP drawing from that same program, are subject to Current Good Manufacturing Practice under 21 CFR 211. The narrow manufacturing flexibilities in 21 CFR 210.2(c) apply to Phase 1 investigational drugs — daraxonrasib, in Phase 3, doesn't qualify for that relief.
- Batch traceability doesn't loosen. Every lot released into an expanded access protocol needs the same batch record, release testing, and deviation documentation a clinical-trial lot gets. A widespread EAP usually means more lots moving through release faster, which is a capacity and staffing question for quality operations, not a documentation shortcut.
- The quality system carries the burden, not the trial. The same documented-procedure, deviation-control, and traceability principles that CGMP and ISO 9001-style quality management systems both build on don't stop at the clinical-trial boundary. A quality system built to support one controlled trial arm has to scale to support a second, less controlled distribution channel without a drop in rigor.
- Audit exposure increases with population size. A widespread treatment protocol creates a larger patient population, a larger set of sites, and a larger volume of product movement for FDA to examine if it inspects the manufacturing or distribution operation. Sites should treat an EAP launch as a trigger for FDA audit preparation, not as a lower-scrutiny side channel:
- Pull the last 12 months of deviation logs for the lots feeding the protocol
- Confirm batch-record change control has been updated for the added release volume
- Check that release-testing staffing can support a shorter turnaround
Compliance Obligations a Sponsor Takes On
Once an EAP is authorized, several obligations attach and stay attached for as long as the protocol runs.
- Public disclosure (FDCA § 561A). Sponsors of drugs for serious or life-threatening diseases must publicly post their expanded access policy, directly or via a link on the company's website.
- Cost recovery is capped (21 CFR 312.8). A sponsor may charge only to recover the direct cost of making the drug available — it isn't a revenue channel.
- Safety reporting is unified (21 CFR 312.32). EAP adverse events feed into the same investigational new drug (IND) safety reporting as the controlled trial, just at higher volume, so pharmacovigilance needs to be resourced for it.
- IRB oversight still applies. Only individual-patient emergency use under 312.310(d) can start before full IRB review; everything else, including a widespread protocol, gets the same institutional review as the trial.
- Informed consent still applies (21 CFR 50). EAP patients consent under the same framework as trial participants.
- Trial enrollment can't be undercut. FDA checks that EAP eligibility criteria aren't pulling patients who'd otherwise enroll in the pivotal trial — a design detail worth getting right with regulatory before submission.
Expanded Access vs. Right to Try
Expanded access is not the only pathway for accessing an unapproved drug. The federal Right to Try Act, signed into law in May 2018, lets eligible patients request certain investigational drugs directly from a manufacturer without FDA authorization, provided the drug has completed a Phase 1 trial and remains in active development.
| Feature | Expanded Access (21 CFR 312, Subpart I) | Right to Try (2018 federal law) |
|---|---|---|
| FDA authorization required | Yes, except narrow emergency cases | No |
| IRB review required | Yes | No |
| Manufacturer participation | Voluntary | Voluntary |
| Trial phase requirement | Under investigation, or trials complete | Completed Phase 1 |
| Adverse event reporting | Feeds sponsor's IND safety reporting under 21 CFR 312.32 | Narrower reporting requirements (21 U.S.C. § 360bbb-0a(d)) |
The daraxonrasib EAP runs through the FDA-authorized pathway, which is the pathway with more built-in oversight and the one that gives FDA visibility into safety signals as the treated population grows before approval.
The Bigger Pattern
Pancreatic cancer has a long history of investigational drugs generating early interest and failing to clear the bar for approval. An authorized EAP doesn't change that history, and it isn't a signal FDA has prejudged the RASolute 302 outcome. What it does confirm is that FDA's expanded access framework, built through Subpart I and reinforced by the Cures Act's public-disclosure requirement, is running the way it's designed to: giving patients facing a serious disease with few alternatives access to an investigational therapy, without shortcutting the trial that determines approval.
For sponsors and their contract development and manufacturing organizations (CDMOs), the operational takeaway isn't specific to pancreatic cancer. A CDMO manufacturing EAP lots doesn't have a direct relationship with FDA — the sponsor holds the IND and carries the regulatory obligation — but the quality agreement between sponsor and CDMO has to flow that obligation down explicitly: who releases each lot, who owns deviation investigation, and who produces batch records on inspection request. An FDA quality agreement drafted for a single-arm Phase 3 supply chain doesn't automatically cover a second, faster-moving distribution channel, and an inspector examining EAP lots will pull the CDMO's records the same way they'd pull the sponsor's. It's worth confirming the quality agreement actually names expanded access, not just the clinical trial, before volume ramps. The broader point is that expanded access is a live, usable pathway with real manufacturing and quality obligations attached, not a niche mechanism reserved for high-profile programs.
If a pipeline asset targets a serious or life-threatening disease with real unmet need, it's worth confirming three things before a physician calls asking about access: that the deviation log for the relevant lots is current, that batch-record change control has been updated for expanded-access volume, and that release-testing staffing can absorb a faster cadence. Sites can benchmark current standing against inspection readiness expectations. For a broader look at how ongoing FDA compliance obligations apply across a drug's lifecycle, that's a conversation worth having with a regulatory and quality team early.
Frequently Asked Questions
What is an FDA expanded access treatment protocol (EAP)? An EAP is a pathway under 21 CFR 312.320 that lets a sponsor make an investigational drug available to a broad population of patients with a serious or immediately life-threatening disease, outside the controlled clinical trial. It requires the drug to already be under investigation, or to have completed its trials, and the sponsor to be actively pursuing marketing approval.
What does FDA's "safe to proceed" letter mean for daraxonrasib? It means FDA reviewed the expanded access submission within the standard 30-day window under 21 CFR 312.40 and did not place it on clinical hold. It authorizes the treatment protocol to begin. It is not a drug approval and doesn't indicate the eventual outcome for daraxonrasib.
Does expanded access change manufacturing requirements? No. Investigational product supplied under an EAP for a Phase 3 program remains subject to Current Good Manufacturing Practice under 21 CFR 211. The Phase 1 manufacturing flexibilities in 21 CFR 210.2(c) don't apply once a drug is in Phase 3, which is where daraxonrasib sits.
How is expanded access different from the Right to Try Act? Expanded access under 21 CFR 312, Subpart I requires FDA authorization and IRB review. The Right to Try Act, signed in May 2018, lets eligible patients request certain investigational drugs directly from a manufacturer without FDA sign-off, provided the drug has completed a Phase 1 trial.
What obligations does a sponsor take on once an EAP is authorized? Four apply on an ongoing basis:
- Maintain IRB oversight at each treating site
- Obtain informed consent under 21 CFR 50
- Limit any cost recovery to direct drug costs under 21 CFR 312.8
- Fold expanded access safety data into ongoing IND safety reporting under 21 CFR 312.32
Sponsors of drugs for serious diseases must also publicly post their expanded access policy under FDCA Section 561A.
Last updated: 2026-08-19
Jared Clark
Principal Consultant, Certify Consulting
Jared Clark is the founder of Certify Consulting, helping organizations achieve and maintain compliance with international standards and regulatory requirements.